Skip to main content

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Recruiting · NCT04674969

Conditions: Peripheral Vascular Diseases

At a glance

Research payments reported, 2025
$734,500
U.S. investigators named
47
Sites paid
50
Planned or actual enrollment
5,000

About the trial

Sponsor
Boston Scientific Corporation
Tested
Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device. (device)
Dates
Started 2021-03-29; completion 2028-01
Results posted
Not yet

The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.

From ClinicalTrials.gov, last updated 2026-10-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $734,500 in research payments for this study in 2025 (469 payments).

Products named: Clinical Trial Product

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.